Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recommendations for Uniform Variant Calling of SARS-CoV-2 Genome Sequence across Bioinformatic Workflows.
Connor R, Shakya M, Yarmosh DA, Maier W, Martin R, Bradford R, Brister JR, Chain PSG, Copeland CA, di Iulio J, Hu B, Ebert P, Gunti J, Jin Y, Katz KS, Kochergin A, LaRosa T, Li J, Li PE, Lo CC, Rashid S, Maiorova ES, Xiao C, Zalunin V, Purcell L, Pruitt KD. Connor R, et al. Among authors: maiorova es. Viruses. 2024 Mar 11;16(3):430. doi: 10.3390/v16030430. Viruses. 2024. PMID: 38543795 Free PMC article.
Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
Pitts J, Li J, Perry JK, Du Pont V, Riola N, Rodriguez L, Lu X, Kurhade C, Xie X, Camus G, Manhas S, Martin R, Shi PY, Cihlar T, Porter DP, Mo H, Maiorova E, Bilello JP. Pitts J, et al. Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0022222. doi: 10.1128/aac.00222-22. Epub 2022 May 9. Antimicrob Agents Chemother. 2022. PMID: 35532238 Free PMC article.
Towards increased accuracy and reproducibility in SARS-CoV-2 next generation sequence analysis for public health surveillance.
Connor R, Yarmosh DA, Maier W, Shakya M, Martin R, Bradford R, Brister JR, Chain PS, Copeland CA, di Iulio J, Hu B, Ebert P, Gunti J, Jin Y, Katz KS, Kochergin A, LaRosa T, Li J, Li PE, Lo CC, Rashid S, Maiorova ES, Xiao C, Zalunin V, Pruitt KD. Connor R, et al. Among authors: maiorova es. bioRxiv [Preprint]. 2022 Nov 3:2022.11.03.515010. doi: 10.1101/2022.11.03.515010. bioRxiv. 2022. Update in: Viruses. 2024 Mar 11;16(3):430. doi: 10.3390/v16030430 PMID: 36380755 Free PMC article. Updated. Preprint.
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
Hollnberger J, Liu Y, Xu S, Chang S, Martin R, Manhas S, Aeschbacher T, Han B, Yazdi T, May L, Han D, Shornikov A, Flaherty J, Manuilov D, Suri V, Asselah T, Lampertico P, Wedemeyer H, Aleman S, Richards C, Mateo R, Maiorova E, Cihlar T, Mo H, Urban S. Hollnberger J, et al. J Hepatol. 2023 Sep;79(3):657-665. doi: 10.1016/j.jhep.2023.04.027. Epub 2023 Apr 27. J Hepatol. 2023. PMID: 37120031 Clinical Trial.
Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV.
Mateo R, Xu S, Shornikov A, Yazdi T, Liu Y, May L, Han B, Han D, Martin R, Manhas S, Richards C, Marceau C, Aeschbacher T, Chang S, Manuilov D, Hollnberger J, Urban S, Asselah T, Abdurakhmanov D, Lampertico P, Maiorova E, Mo H. Mateo R, et al. JHEP Rep. 2023 Aug 22;5(11):100893. doi: 10.1016/j.jhepr.2023.100893. eCollection 2023 Nov. JHEP Rep. 2023. PMID: 37929228 Free PMC article.